Core Insights - Keiretsu Forum Mid-Atlantic, South-East, and Texas (K4-MST) and MDB Capital Holdings successfully hosted two investor-focused events aimed at transforming early-stage capital approaches [1][2] Group 1: Event Overview - The Southeast Investor Conference took place on July 29-30 at Georgia Tech, focusing on accredited investors and family offices, featuring educational sessions and structured networking [3][5] - The Mid-Atlantic Investor Summit was held on November 19-20 at Drexel University, emphasizing disciplined portfolio strategies and faster exits [5][6] Group 2: Key Themes and Discussions - Both events aimed to shift discussions from market challenges to collaborative solutions, showcasing curated deal flow and real data on returns [4][10] - The conferences included presentations from approximately 75 accredited investors and showcased 10 diligence-ready companies, focusing on sectors like AI, MedTech, and FinTech [7][8] Group 3: Future Plans - K4-MST and MDB Capital announced plans for a series of Investor Summits in 2026, with events scheduled in Dallas, Atlanta, and Philadelphia [10][15] - The upcoming summits will continue to emphasize syndication, investor education, and pathways to quicker exits, aiming to align angel investing with public venture pathways [14][15]

Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for the first three quarters of the year and expects significant revenue in the fourth quarter to offset operating expenses [30][31] - The company aims to cover operating expenses through financings and anticipates a good fourth quarter [31][32] - The market value of the company's stock is currently undervalued compared to its significant equity holdings in companies like Exazyme and Heartbeat [32][33] Business Line Data and Key Metrics Changes - The company is focused on launching three to five companies per year to build a public venture portfolio, which is a shift from the historical rate of one company every 18 months [9][24] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than past ones [24][27] Market Data and Key Metrics Changes - The microcap market has been challenging, but the company believes it is on the verge of a resurgence due to increased demand for public companies with revenue and earnings [28][50] - There is a growing trend of companies seeking to go public as private equity and venture capital funding becomes less attractive [55][56] Company Strategy and Development Direction - The company aims to create a sustainable business model that can survive beyond its founders by scaling operations and launching more companies [9][24] - The focus is on curating high-potential companies and transforming them into investable public entities with significant growth potential [12][13] - The company is also exploring the potential of a spinout in the patent law sector, which could provide substantial value [34][64] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges in the microcap market but remains optimistic about future opportunities and the potential for public venture to thrive again [28][30] - The company is committed to improving communication with shareholders and enhancing investor relations to better convey its value proposition [68][70] Other Important Information - The company is preparing for the IPO of Buddha Juice and expects to close multiple deals in the near future, indicating a busy pipeline [27][40] - Management emphasizes the unique value proposition of their public venture platform, which differentiates them from traditional private equity and venture capital firms [16][39] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The company prefers to wait until there is a developed market for the stock and broader ownership before considering dividends [42] Question: Will shareholders retain the same percentage of ownership as Exazyme raises funds? - Shareholders will experience dilution as companies raise more capital, but efforts will be made to minimize this [43] Question: What is the outlook for Heartbeat regarding FDA approval? - The company is optimistic about FDA approval and believes it will facilitate future fundraising efforts [46] Question: Why is the stock trading at a low price compared to the IPO? - The poor performance of the microcap market and concerns about the company's ability to select successful investments are contributing factors [48][49] Question: What makes the cost of being public more favorable for listings? - Companies that are profitable and growing in the microcap sector are trading at attractive valuations, making public listings more appealing [50][51] Question: Can you clarify the PatentVest spinout and its potential market value? - The spinout is expected to have substantial market value due to the disruption AI will bring to the legal sector, particularly in patent law [63][66]

Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for the first three quarters of the year and expects significant revenue in the fourth quarter to offset operating expenses [30][31] - The company aims to cover operating expenses through financings and anticipates a good fourth quarter [31][32] - The market value of the company's equity holdings in Pollex Bio and Buda Juice is expected to provide substantial upside for shareholders [31][32] Business Line Data and Key Metrics Changes - The company is focused on launching three to five companies per year to build a public venture portfolio, which is a shift from the historical rate of one company every 18 months [9][24] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than past ones [24][27] Market Data and Key Metrics Changes - The microcap market has been challenging, but the company believes that transparency and liquidity in public markets will become attractive again [28][30] - There is a growing demand for small public companies with revenue and earnings, as many are moving towards private equity routes [29][30] Company Strategy and Development Direction - The company aims to create a sustainable operational framework to support the launch of public venture companies and believes it has a unique position in the market [16][39] - The strategy includes curating and positioning companies for success in the public markets, focusing on those with significant growth potential [10][15] - The company is also exploring the potential of a spinout in the patent law sector, which could provide substantial value [34][64] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges in the microcap market but remains optimistic about future opportunities and the potential for public venture to thrive [28][30] - The company is committed to improving communication with shareholders and addressing concerns about stock performance [68][70] Other Important Information - The company has a unique model that combines operational support with equity positions in the companies it helps launch, which differentiates it from traditional underwriters and VCs [21][39] - The company is actively working on building its community to support its ventures and enhance its operational capabilities [25][26] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The company prefers to wait until there is a developed market for the stock and broader ownership before considering dividends [42] Question: How will MDB handle ownership percentages during fundraising for Exazyme? - Shareholders can expect dilution as companies raise more capital, but efforts will be made to minimize this [43] Question: What is the outlook for Heartbeat regarding FDA approval? - The company is optimistic about FDA approval and believes it will facilitate future fundraising efforts [46] Question: Why is the stock trading at a low price compared to the IPO? - The poor performance of the microcap market and concerns about the company's ability to select successful ventures are contributing factors [48] Question: What makes the cost of being public more favorable for listings? - Companies that are profitable and growing in the microcap sector are trading at attractive valuations, making public listings more appealing [50][51] Question: Can you clarify the PatentVest spinout and its potential? - The spinout is expected to have substantial market value due to the disruption AI will bring to the legal sector, particularly in patent law [63][66]

Financial Data and Key Metrics Changes - The company has used approximately $5.9 million for operating expenses in the first three quarters of 2025, with expectations of significant revenue in the fourth quarter to offset these expenses [30][31] - The company anticipates a good fourth quarter, which will help cover operating expenses through the number of financings being conducted [31][32] - The market value of the company's equity holdings in Pollex Bio and Buddha Juice is expected to provide substantial upside for shareholders [31][32] Business Line Data and Key Metrics Changes - The company aims to scale its operations to launch three to five companies per year, moving from a historical average of one launch every 18 months [9][23] - The company has a deep pipeline of opportunities and believes that future launches will have a better probability of success than historical ones [23][24] Market Data and Key Metrics Changes - The microcap market has been challenging, but there is optimism that transparency and liquidity in public markets will become attractive again [28][29] - The company is seeing a resurgence in demand for small public companies, as many are moving away from private equity and venture capital routes [29][51] Company Strategy and Development Direction - The company is focused on building a unique public venture platform that supports the launch of public companies, emphasizing the importance of operational bandwidth and community involvement [9][15] - The strategy includes curating high-potential companies and transforming them into investable public entities, with a focus on both deep tech and consumer products like Buddha Juice [12][58] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current market challenges but remains optimistic about the future of public venture, believing that the company is well-positioned to capitalize on upcoming opportunities [28][39] - The management is committed to improving communication with shareholders and addressing concerns about the company's stock performance [68][70] Other Important Information - The company is exploring the potential of a spinout involving PatentVest, which is expected to disrupt the patent law sector significantly [34][63] - The company is also working on enhancing its investor relations efforts to better communicate its value proposition and portfolio performance [68][70] Q&A Session Summary Question: When can shareholders expect to see a dividend? - The management's philosophy is to distribute dividends when the company has a developed market and broader ownership, avoiding any hindrance to company development [41] Question: How will MDB handle dilution during fundraising for Exazyme? - Shareholders can expect dilution as companies raise more capital, but efforts will be made to minimize this dilution [42] Question: What is MDB's role regarding Heartbeat and its FDA approval? - The management emphasizes the importance of FDA approval for Heartbeat, which will facilitate future fundraising efforts [45] Question: Why is the stock trading at a low price compared to its IPO? - The management attributes the low stock price to a poor microcap market, concerns about the company's ability to select successful ventures, and year-end tax selling [46][47] Question: What makes the cost of being public more favorable for listings? - The management believes that profitable microcap companies are trading at attractive valuations, making it sensible for them to go public [49][51] Question: How does MDB differentiate between deep tech and consumer products like Buddha Juice? - The management clarifies that both categories are viable, with a focus on launching category leaders that have a competitive edge [57][58]

NASDAQ: MDBH The Premier Public Venture Platform We launch game-changing companies Third Quarter 2025 Update November 20, 2025 Forward-Looking Statements This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "g ...

Core Viewpoint - MDB Capital Holdings is making significant progress in scaling its public venture platform and aims to create a diversified portfolio of high-potential public venture opportunities [3]. Operational Highlights - The company anticipates closing two offerings shortly: a $16.8 million private placement for Paulex Bio, focused on diabetes therapeutics, and a $20 million IPO for Buda Juice, which offers UltraFresh™ cold-crafted juices [8]. - MDB Capital has expanded its pipeline of early-stage, disruptive companies that have the potential to lead in new categories [8]. - The firm is improving the efficiency of its public venture platform to better identify and prepare new category-leading companies with disruptive technologies [8]. - MDB welcomed TCA Venture Group and Keiretsu Forum MST angel group investors into its latest offerings, enhancing its investor community [8]. - The company has broadened relationships with Registered Investment Advisors (RIAs) to attract new investors seeking alternative investment strategies [8].

Financial Performance - The net operating loss for the three months ended September 30, 2025, was $3.76 million, compared to a loss of $8.72 million for the same period in 2024, indicating a 56.9% improvement[10]. - The company reported a net loss of $4.66 million for the three months ended September 30, 2025, compared to a loss of $7.74 million in the same period of 2024, showing a reduction of 39.5%[10]. - Net loss for the nine months ended September 30, 2025, was $19,508,201, compared to a net loss of $20,855,682 for the same period in 2024, indicating a decrease of approximately 6.4%[14]. - The net loss attributable to MDB Capital Holdings, LLC for the nine months ended September 30, 2025, was $19,491,804[85]. - The net loss for the nine months ended September 30, 2025, was $(5,816,310), a 35.5% increase from $(4,293,474) in 2024[152]. Revenue and Income - Fee income for the nine months ended September 30, 2025, increased to $2.14 million, up from $1.30 million in 2024, reflecting a growth of 64.5%[10]. - For the nine months ended September 30, 2025, total operating income was $178,570, a decrease of $835,246 or 82.4% from $1,013,816 in 2024[146]. - Fee income for the nine-month period increased to $2,140,238, up $836,840 or 64.2% from $1,303,398 in 2024[146]. - The company reported a gain related to dilution events of $19,863 for both the three and nine-month periods, marking a 100% increase from no gain in the previous year[146]. Assets and Liabilities - As of September 30, 2025, total assets decreased to $61.51 million from $71.98 million as of December 31, 2024, representing a decline of approximately 14.5%[8]. - Total liabilities remained relatively stable at $1.88 million as of September 30, 2025, compared to $1.90 million as of December 31, 2024[8]. - Cash and cash equivalents decreased to $15.09 million as of September 30, 2025, down from $20.44 million at the end of 2024, a decline of 26.3%[8]. - The equity method investment decreased to $38.74 million as of September 30, 2025, from $41.76 million at the end of 2024, a decrease of 7.2%[8]. - The company had an accumulated deficit of $(18,049,729) as of September 30, 2025, compared to an accumulated income of $1,442,075 on December 31, 2024[8]. Cash Flow - The total cash used in operating activities for the nine months ended September 30, 2025, was $5,323,638, compared to $8,620,720 in 2024, showing an improvement of approximately 38.5%[14]. - Cash used in operating activities for the nine months ended September 30, 2025, was $5,323,638, an improvement from $8,620,720 in 2024, indicating a reduction of about 38.5%[14]. - The company had a net cash provided by investing activities of $(25,677) for the nine months ended September 30, 2025, compared to $20,045,260 in 2024, indicating a significant decline[14]. Costs and Expenses - General and administrative costs for the nine months ended September 30, 2025, totaled $17,236,426[85]. - Stock-based compensation for the nine months ended September 30, 2025, was $9,066,067, down from $11,717,587 in 2024, reflecting a reduction of about 22.6%[14]. - Total operating costs for the nine months ended September 30, 2025, were $17,236,426, down from $22,805,340 in 2024, representing a decrease of about 24.5%[10]. - Compensation expenses decreased to $3,317,168 for the three-month period, down $1,853,604 or 35.8% from $5,170,772 in 2024[145]. Investment and Financing - The company completed an initial public offering (IPO) on September 20, 2023, raising gross proceeds of $19,999,992 from the sale of 1,666,666 shares at $12.00 per share[22]. - The company has a revolving credit facility with a commitment of up to $2,000,000, with a current interest rate of 6.75%[59]. - The Company recognized no income tax expense for the nine months ended September 30, 2025, due to a full valuation allowance against net deferred tax assets[132]. Research and Development - Research and development costs for the nine months ended September 30, 2025, were $0, compared to $1.24 million in 2024, indicating a strategic shift in R&D spending[10]. - Research and development costs were $0 for the three-month period, a decrease of $723,487 or 100% compared to $723,487 in 2024[145]. Market and Economic Conditions - The company is monitoring potential recession risks that could impact the overall business environment and capital markets[185].

Core Points - MDB Capital Holdings, LLC plans to host a Zoom webinar on November 20, 2025, at 4:30 p.m. Eastern Time to provide a business update for Q3 2025 [1] - The call will be led by CEO Christopher Marlett, who may be joined by other management team members to discuss recent developments, ongoing initiatives, and anticipated milestones [2] - Investors can pre-register for the webinar and access it through MDB's investor relations website [2] Company Overview - MDB Capital Holdings, LLC, founded in 1997, focuses on launching disruptive technology companies through a unique public venture capital approach [3] - The firm emphasizes community-driven financings of early-stage leaders via early public offerings, primarily on NASDAQ, and post-IPO offerings for qualifying companies [3] - MDB Capital operates under the MDB Capital brand, which includes subsidiaries like MDB Capital, a venture-focused broker-dealer, and PatentVest, an integrated IP strategy and law firm [3]

Core Insights - The convergence of consumer technology, ambulatory monitoring, and traditional medical systems is reshaping cardiac care, with intellectual property control being a key determinant for leadership in diagnostics [1][4] - Cardiovascular disease is the leading cause of death globally, with a significant market opportunity of $133 billion for portable, connected diagnostic systems [2][4] Company Analysis - Major players in consumer wearables such as Apple, Samsung, Google/Fitbit, and others have introduced heart rate tracking and single-lead ECGs, but these technologies are limited to rhythm screening and do not achieve the diagnostic accuracy of 12-lead ECGs [7] - Companies like HeartBeam, iRhythm, and AliveCor are advancing portable systems that aim for diagnostic-grade performance, with HeartBeam being the first to offer a cable-free 12-lead ECG [7] Intellectual Property Landscape - PatentVest's analysis identified 581 patent families across 243 organizations, highlighting a competitive landscape where traditional device manufacturers like Philips and GE Healthcare face challenges from emerging innovators such as HeartBeam and AliveCor [7]

Summary of MDB Capital Holdings Conference Call Company Overview - **Company**: MDB Capital Holdings (NasdaqCM:MDBH) - **Focus**: Transitioning microcap companies into public ventures, emphasizing a curated approach to launching meaningful companies [1][2] Industry Insights - **Microcap Market**: The microcap sector has seen a significant decline, with the number of public companies dropping from 7,300 to 4,300 over the past 30 years [1] - **Investor Sentiment**: There is a growing disillusionment with traditional private equity and venture capital, leading to increased interest in public ventures [2] - **Market Dynamics**: MDB Capital Holdings aims to capitalize on the scarcity of profitable companies under $300 million market cap, with only 34 identified that meet specific growth criteria [2] Core Strategies and Initiatives - **Scaling Operations**: MDB Capital Holdings plans to increase its IPO launches from one every 18 months to three or four per year [1][16] - **Focus on Leadership**: The company emphasizes the importance of leadership in new technology categories, aiming to take companies public that are leaders in their respective fields [15] - **Unique Offerings**: MDB Capital Holdings has developed a self-clearing broker-dealer platform to facilitate easier access for investors, particularly targeting younger demographics [5][7] Financial Performance and Projections - **IPO Success Rate**: MDB Capital Holdings has a 100% success rate in taking companies public, with 30% achieving billion-dollar market valuations and 60% reaching $500 million or more [9] - **Current Market Cap**: The company's current market cap is $35 million, with a focus on long-term investor relationships for future IPOs [10][11] Future Opportunities - **Metabolic Health Focus**: The company is exploring opportunities in the metabolic health sector, which is identified as a significant market challenge, potentially leading to billion-dollar companies [17] - **Public Venture Revolution**: MDB Capital Holdings invites submissions for innovative ideas, aiming to build relationships and foster new leadership in technology [17] Additional Insights - **Tax Advantages**: All companies under MDB Capital Holdings qualify for QSBS 1201, providing tax benefits for investors [20] - **Market Conditions**: The capital markets for small-cap IPOs have faced challenges, but there is optimism for recovery as new companies emerge [21] - **Portfolio Management**: MDB Capital Holdings acts as a launchpad for companies, aiming to transition them to independence once they reach maturity [23] Conclusion MDB Capital Holdings is strategically positioned to leverage the current market dynamics in the microcap sector, focusing on leadership, innovative public ventures, and a unique investor community to drive future growth and success.